Eisai releases Nov1. ASTX guidance for royalties is $70M for 2012. They have already reached $35M (1Q12 20.5M and 2Q12 14.4M).
The 3Q11 was 16,6M, I believe we hit 17.5M-18.5M for the 3Q12
Expenses have hovered near $20M per quarter. The question here is the discontinuation on Mp-470, do they write off some surprise cost, do they save some expenses, since the trial was halted?
Knowing ASTX we get some bad surprise here.
How do they treat the $6M in appreciation on SRPT? In 2008 they wrote down this investment by $3M. I see a $2M loss for the quarter. However cash and securities will grow $6M.
At todays value on SRPT the 4th quarter will see 3.2M +5M milestone added to cash position.
Plus any sales of Dacogen for aml. Throw in all the updates at ASH, we should trade higher.